Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 112INDUSTRY 9OTHER_GOV 3UNKNOWN 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 41Colonic Neoplasms 40Lung Neoplasms 39Leukemia 36Rectal Neoplasms 34Lymphoma 34Colorectal Neoplasms 33Prostatic Neoplasms 24Multiple Myeloma 23Lymphoma, Follicular 22Leukemia, Myeloid, Acute 19Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Melanoma 16Head and Neck Neoplasms 15Urinary Bladder Neoplasms 14Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Burkitt Lymphoma 14Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Leukemia, Erythroblastic, Acute 12

Interventions

Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NIH × Nasopharyngeal Carcinoma × Clear all
NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
15 enrolled 17 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡